| $385M | ||
| $350M | ||
| $215M | ||
| $82M | ||
| $76M | ||
| $62M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.
Over the last 12 months, insiders at Alaunos Therapeutics, Inc. have bought $0 and sold $0 worth of Alaunos Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Alaunos Therapeutics, Inc. have bought $969,543 and sold $13,711 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 750,000 shares for transaction amount of $487,500 was made by Postma Robert W (director) on 2022‑11‑29.
| 2024-12-31 | Sale | Vieser Jaime | director | 3,000 0.1921% | $2.01 | $6,022 | +38.22% | |
| 2023-09-01 | Sale | Boyle Kevin S. Sr. | Chief Executive Officer | 68,014 0.0277% | $0.14 | $9,542 | -40.66% | |
| 2022-11-29 | Postma Robert W | director | 750,000 0.3334% | $0.65 | $487,500 | -26.47% | ||
| 2022-11-29 | Vieser Jaime | director | 1.25M 0.5557% | $0.65 | $812,500 | -26.47% | ||
| 2021-12-22 | Sale | De Groot Eleanor | EVP, Operations | 20,132 0.0094% | $1.27 | $25,568 | -25.70% | |
| 2021-11-17 | Boyle Kevin S. Sr. | Chief Executive Officer | 9,116 0.0044% | $1.40 | $12,762 | -20.22% | ||
| 2021-11-16 | Boyle Kevin S. Sr. | Chief Executive Officer | 884 0.0004% | $1.40 | $1,238 | -22.70% | ||
| 2021-09-29 | Vieser Jaime | director | 100,000 0.0464% | $1.91 | $191,000 | -40.63% | ||
| 2021-09-02 | Postma Robert W | director | 75,000 0.0342% | $1.73 | $129,750 | -35.59% | ||
| 2021-09-02 | Hagen Heidi | director | 23,770 0.011% | $1.76 | $41,835 | -35.59% | ||
| 2021-09-01 | Weis Holger | director | 50,000 0.0238% | $1.83 | $91,500 | -36.31% | ||
| 2021-09-01 | Huang James | director | 100,000 0.0445% | $1.71 | $171,000 | -36.31% | ||
| 2021-01-08 | Sale | Buck Jill | EVP, GM Gene Therapy | 27,894 0.0129% | $3.12 | $87,029 | -22.47% | |
| 2021-01-08 | Sale | Hadfield Robert | General Counsel and Secretary | 26,500 0.0122% | $3.12 | $82,680 | -22.47% | |
| 2021-01-08 | Sale | Lafond Kevin G | SVP, Treasurer & CAO | 18,020 0.0082% | $3.09 | $55,682 | -22.47% | |
| 2021-01-04 | Sale | Cooper Laurence James Neil | President and CEO | 105,693 0.0475% | $2.71 | $286,428 | -9.93% | |
| 2021-01-04 | Sale | De Groot Eleanor | EVP, GM Cell Therapy | 21,620 0.0097% | $2.72 | $58,806 | -9.93% | |
| 2020-01-02 | Sale | MAUNEY DAVID M MD | President | 22,394 0.011% | $4.55 | $101,893 | -37.61% | |
| 2020-01-02 | Sale | De Groot Eleanor | EVP, GM Cell Therapy | 24,890 0.0123% | $4.55 | $113,250 | -37.61% | |
| 2020-01-02 | Sale | Buck Jill | EVP, GM Gene Therapy | 27,923 0.0138% | $4.55 | $127,050 | -37.61% |
| Postma Robert W | director | 5000000 224.0315% | $18.05M | 2 | 0 | <0.0001% |
| Cooper Laurence James Neil | President and CEO | 1799280 80.6191% | $6.5M | 1 | 2 | <0.0001% |
| Boyle Kevin S. Sr. | Chief Executive Officer | 798236 35.766% | $2.88M | 2 | 1 | <0.0001% |
| De Groot Eleanor | EVP, Operations | 237106 10.6238% | $855,952.66 | 0 | 3 | |
| Buck Jill | EVP, GM Gene Therapy | 199516 8.9396% | $720,252.76 | 0 | 2 | |
| MAUNEY DAVID M MD | President | 195278 8.7497% | $704,953.58 | 1 | 1 | <0.0001% |
| Hagen Heidi | director | 145889 6.5367% | $526,659.29 | 1 | 0 | <0.0001% |
| WEISER MICHAEL | director | 135945 6.0912% | $490,761.45 | 0 | 1 | |
| Hadfield Robert | General Counsel and Secretary | 133319 5.9735% | $481,281.59 | 0 | 2 | |
| Weis Holger | director | 120167 5.3842% | $433,802.87 | 1 | 0 | <0.0001% |
| Huang James | director | 108333 4.854% | $391,082.13 | 1 | 0 | <0.0001% |
| KIRK RANDAL J | 100000 4.4806% | $361,000.00 | 14 | 0 | +1.39% | |
| Fowler Wyche | director | 72500 3.2485% | $261,725.00 | 1 | 0 | +0.2% |
| Lafond Kevin G | SVP, Treasurer & CAO | 63965 2.866% | $230,913.65 | 0 | 4 | |
| BELBEL CAESAR J | COO, CLO, and Secretary | 59201 2.6526% | $213,715.61 | 0 | 1 | |
| Vieser Jaime | director | 25894 1.1602% | $93,477.34 | 2 | 1 | <0.0001% |
| BRENNAN MURRAY | director | 12500 0.5601% | $45,125.00 | 0 | 3 | |
| LEBEL FRANCOIS | Executive Vice President R&D | 0 0% | $0 | 0 | 1 |
$17,168,388 | 54 | -43.55% | $10.26M | |
$1,029,337 | 36 | -28.38% | $7.83M | |
Alaunos Therapeutics, Inc. (TCRT) | $63,749,694 | 24 | -12.24% | $8.06M |
$37,200,153 | 21 | -47.67% | $8.25M | |
$1,039,491 | 21 | -11.76% | $6.84M | |
$79,536,861 | 15 | -6.81% | $9.83M | |
$188,726 | 11 | -28.87% | $8.17M | |
$20,759,738 | 11 | -44.68% | $9.92M | |
$120,379 | 10 | -24.48% | $7.28M | |
$11,777,042 | 10 | -11.94% | $9.33M | |
$90,087 | 9 | 20.06% | $9.68M | |
$241,042 | 9 | -11.02% | $8.81M | |
$211,895 | 8 | -39.70% | $7.03M | |
$159,974 | 7 | -18.60% | $6.45M | |
$149,996 | 5 | 16.26% | $8.74M | |
$1,184,658 | 4 | -22.17% | $7.38M | |
$28,395 | 3 | 3.48% | $7.97M | |
$1,057,000 | 3 | 5.27% | $6.54M | |
$31,190 | 2 | -14.18% | $6.9M |
| Increased Positions | 8 | +22.86% | 44,326 | +67.75% |
| Decreased Positions | 11 | -31.43% | 1,206 | -1.84% |
| New Positions | 6 | New | 31,292 | New |
| Sold Out Positions | 5 | Sold Out | 296 | Sold Out |
| Total Postitions | 32 | -8.57% | 108,550 | +65.9% |
| Blackrock, Inc. | $70.00 | 1.07% | 21,353 | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $69.00 | 1.05% | 20,972 | 0 | 0% | 2025-09-30 |
| Geode Capital Management, Llc | $52.00 | 0.79% | 15,791 | -155 | -0.97% | 2025-09-30 |
| Morgan Stanley | $6.00 | 0.08% | 1,684 | -114 | -6.34% | 2025-09-30 |
| Tower Research Capital Llc (Trc) | $5.00 | 0.08% | 1,633 | +660 | +67.83% | 2025-09-30 |
| Ubs Group Ag | $5.00 | 0.08% | 1,533 | -5,282 | -77.51% | 2025-09-30 |
| Osaic Holdings, Inc. | $4.00 | 0.06% | 1,165 | +470 | +67.63% | 2025-09-30 |
| Cibc Private Wealth Group Llc | $1.00 | 0.02% | 300 | 0 | 0% | 2025-09-30 |
| Royal Bank Of Canada | $1.00 | 0.01% | 198 | +198 | New | 2025-09-30 |
| Wells Fargo & Company/Mn | $1.00 | 0.01% | 183 | 0 | 0% | 2025-09-30 |